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not have PORT. It seems important to evaluate modern post-operative 
radiotherapy in randomised trials as the number of patients with nodal 
involvement is increasing because of better surgery and the recent posi-
tive results of adjuvant chemotherapy. As in breast cancer or rectal can-
cer, it is time to better establish the role of post-operative radiotherapy 
in such a frequent tumour as lung cancer. A large, multi-institutional 
European phase III trial Lung ART (Lung Adjuvant Radiotherapy Trial) 
joint effort of several groups: IFCT, EORTC lung and radiation oncol-
ogy group, LARS-G and FNCLCC will soon start comparing confor-
mal PORT to no PORT, and will include patients who have proven N2 
disease and complete resection whether they have had or not, adjuvant 
or neo-adjuvant chemotherapy (Le Pechoux et al, 2007]. 
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It is clear that only some patients beneﬁt from systemic adjuvant 
therapy. This is the group of patients who have residual micrometas-
tases that are sensitive to adjuvant therapy. Patients with R0 resection 
of their tumor, without micrometastases are cured with local/regional 
therapy, whereas those with residual micrometastases that are resistant 
to adjuvant therapy do not respond to adjuvant therapy. There is there-
fore a need to identify factors that would allow for the identiﬁcation of 
patients most likely to beneﬁt from adjuvant chemotherapy. 
A potential predictive marker of bone metastases has recently been 
identiﬁed in patients with completely resected NSCLC that is also as-
sociated with survival outcome [1]. We investigated the presence of 10 
different markers involved in bone resorption or development of metas-
tases in 30 patients with resected NSCLC who subsequently developed 
bone metastases, and compared the results of this patient group with 
those of 30 patients with resected NSCLC without metastases and of 
26 patients with resected NSCLC who developed non-bone metastases. 
The expression of bone sialoprotein (BSP) was strongly correlated with 
the development of bone metastases (p < 0.001). Median survival was 
signiﬁcantly shorter in patients expressing BSP compared with those 
not expressing BSP (25 vs 39 months, p = 0.02) (Fig. 1). These data 
suggest that patients with tumors expressing BSP are at high risk of 
developing bone metastases and may therefore be more likely to beneﬁt 
from adjuvant chemotherapy or other preventive treatments. 
Another approach to identifying patients most likely to beneﬁt from ad-
juvant therapy is to use pharmacogenomics. This involves the analysis 
of molecular markers in tumors at the genetic level using polymerase 
chain reaction (PCR) techniques to analyze gene mutations and/or the 
level of gene expression. Various genetic markers that are predictive of 
increased or decreased sensitivity to various cytotoxic agents have been 
identiﬁed (Table 2) [2-4]. 
We performed a retrospective analysis of the expression of three genes 
and their potential correlation with survival in patients with advanced 
NSCLC treated with gemcitabine or gemcitabine/cisplatin [4]. The 
expression levels of excision repair cross-complementation 1 (ERCC1), 
ribonucleotide reductase M1 (RRM1) and epidermal growth factor 
receptor (EGFR) were determined by real-time PCR from 70 forma-
lin-ﬁxed, parafﬁn-embedded bronchoscopic/ﬁne-needle aspiration 
biopsies. ERCC1 and RRM1 but not EFGR were strongly correlated 
with overall survival; low levels of ERCC1 and RRM1 expression were 
associated with a signiﬁcantly longer survival compared to patients 
with higher levels of expression of these two genes. These data suggest 
that ERCC1 and RRM1 are appropriate genetic markers that could be 
used to select patients likely to beneﬁt from adjuvant therapy. Indeed, 
this approach is being used in an ongoing study in patients with stage 
IIIB/IV disease in which patients receive 1 of 4 different chemotherapy 
regimens according to the level of expression of RRM1 and ERCC1 
on their tumors. This approach is expected to yield a superior overall 
survival compared with historical data in this patient population. 
Another retrospective study investigated whether the presence of the 
genetic marker ERCC1 could be used to predict if a patient will beneﬁt 
from adjuvant chemotherapy compared with no further treatment [5]. 
This study analyzed data from the IALT in which patients were ran-
domized to receive cisplatin-based chemotherapy or observation. The 
study found that with adjuvant chemotherapy, survival was signiﬁcant-
ly longer in patients with ERCC1-negative tumors (adjusted HR 0.65, 
95% CI 0.50-0.86, p = 0.002), but not in patients with ERCC1-positive 
tumors (adjusted HR 1.14, 95% CI 0.84-1.55, p = 0.40) [13]. However, 
for patients who did not receive adjuvant chemotherapy, survival was 
signiﬁcantly longer in those with ERCC1-positive tumors compared 
to those with ERCC1-negative tumors (adjusted HR 0.66, 95% CI 
0.49-0.90, p = 0.009). Thus, ERCC1 expression may be an independent 
predictor of the beneﬁt of chemotherapy in patients with NSCLC.
The use of pharmacogenomics to predict response to therapy has 
been taken a step further by Potti et al. who have developed a model 
to predict therapeutic outcome based on gene expression proﬁles [6]. 
This technique involves analysis of total RNA from tumor cells, rather 
than following the expression of particular genes. Using this method, 
the authors developed a model that predicted disease recurrence with 
an overall accuracy of 93%, compared with 64% for a model based 
on clinical parameters (age, sex, tumor diameter, stage of disease, 
histological subtype and smoking history). When the accuracy of the 
pharmacogenomic model was assessed using data from 2 further stud-
ies, the accuracy was found to be 79% and 72%, thus validating the 
model. These data suggest that analysis of gene expression proﬁles can 
be used to predict patients for whom adjuvant chemotherapy may be 
appropriate.
This study also investigated whether the model based on gene expres-
sion proﬁles could be used to identify patients with stage IA disease 
at risk of recurrence. Previous studies have shown that approximately 
25% of patients with stage IA disease have disease recurrence within 5 
years, but markers for identifying such patients have not been devel-
oped. In this study, the model of gene expression proﬁles was used 
to identify patients with stage IA disease with a high or low risk of 
recurrence. Kaplan-Meier survival plots for the two subgroups revealed 
a 4-year survival of less than 10% for the high-risk group compared 
with approximately 90% for the low-risk group. These data suggest that 
analysis of gene expression proﬁles can be used to identify high- and 
low-risk groups of patients with stage IA disease. This information 
could help identify patients with stage IA disease for whom adjuvant 
chemotherapy may be appropriate. 
On the basis of the ﬁndings from this study, the CALGB (study 30506) 
has developed a randomized phase II trial in which 138 patients with 
operable stage I disease will be assigned to a predicted outcome of 
low- or high-risk of recurrence by gene expression analysis. Patients 
identiﬁed as low risk will be observed according to standard practice. 
Those identiﬁed as high risk will be randomized to either adjuvant 
chemotherapy or observation only. 
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Anemia is common among patients with lung cancer (1,2). Patients 
with lung cancer have the highest incidence of anemia among patients 
with solid tumors. Frequency and severity of anemia depend on tumor 
stage, duration of the cancer and intensity of anticancer therapy. 
Cancer-related anemia can be caused by myelosuppressive chemo-
therapy and radiotherapy, tumor involvement of the bone marrow, 
relative deﬁciency of erythropoietin, inappropriate response of the bone 
marrow, functional iron deﬁciency, nutritional deﬁciencies, bleeding, 
hemolysis, cytokines and other factors (1,2). A special type of cancer-
related anemia is the anemia of chronic disease which is due to mainly 
an impaired bone marrow response to erythropoietin and partly a rela-
tive inadequacy of erythropoietin production. 
Anemia leads to a wide range of symptoms, impairs health-related 
quality of life, might delay cancer therapy or even affect its outcome 
(1). The severity of symptoms depends on the absolute Hb level, the 
rapidity of onset, compensatory mechanisms, co-morbidity and other 
factors. In patients with lung cancer, the symptoms of anemia are often 
enhanced by diminished pulmonary function and other co-morbidities. 
Adequate assessment of anemia should focus on its symptoms and 
severity, laboratory ﬁndings including storage iron as well as vitamin 
levels, impact on activities of daily living, and potential causes. Multi-
dimensional instruments such as the Linear Analog Scale Assessment 
(LASA) and the Functional Assessment of Cancer Therapy-Anemia 
(FACT-Anemia) scales allow a more detailed assessment of the impact 
of anemia on quality of life. Anemic patients with lung cancer also 
have an increased risk of death. 
Treatment of anemia should attempt to correct the cause of anemia. 
Symptomatic treatment includes red blood cell (RBC) transfusions and 
the use of erythropoiesis stimulating agents (ESAs). 
RBC transfusions result in immediate but often only transient improve-
ment of anemia-related symptoms. Transfusions are of greater clinical 
relevance in lung cancer than in other cancers. Patients usually receive 
transfusions when the Hb levels drop below 10 g/dl or even 8 g/dl. This 
practice results in insufﬁcient treatment of anemia in many patients. 
ESAs (epoetin alfa, epoetin beta, darbepoetin alfa) increase or maintain 
Hb levels, decrease RBC transfusions, reduce anemia-related symp-
toms and improve overall quality of life (3). In lung cancer, the clinical 
beneﬁts of ESAs have been demonstrated for patients undergoing 
chemotherapy or chemoradiotherapy (for review see ref. 4).
Several practice guidelines have been published (5, 6). According to the 
practice guidelines of the American Society of Clinical Oncology and 
the American Society of Hematology (5), epoetins are recommended as 
a treatment option for patients with chemotherapy-associated anemia 
and a Hb concentration that has declined to a level equal to or less than 
10 g/dl, but the use of red blood cell transfusions is also considered 
a treatment option depending on the severity of anemia or clinical 
circumstances. For patients with declining Hb levels but less severe 
anemia (those with hemoglobin >12 g/dl but who have never fallen 
below 10 g/dl), the decision whether to use epoetin immediately or to 
wait until Hb levels fall closer to 10 g/dl should be determined by clini-
cal circumstances and red blood cell transfusion is also a therapeutic 
option when warranted by severe clinical conditions. 
Treatment with ESAs is usually well tolerated (3, 4, 7 - 9). Side ef-
fects include hypertension and thromboembolic events. ESAs increase 
the risk of hypertension by 1.25-fold and the risk of thromboembolic 
events by 1.67-fold (7). However, each of these side effects occurs in 
fewer than 10% of the patients. Other occasional side effects are skin 
reactions, cephalea and inﬂuenza-like symptoms. The development of 
anti-erythropoietic antibodies or pure red cell aplasia is not a problem 
in patients with cancer.
Because anemia contributes to tumor hypoxia, erythropoietic protein-
mediated control of anemia could improve tumor hypoxia and, thereby, 
improve both response to chemotherapy or radiotherapy which then 
could translate into improved survival. 
Previous randomized trials suggested that ESAs might result in im-
proved survival in anemic patients undergoing chemotherapy (8, 9). 
Two subsequent trials in patients with metastatic breast cancer undergo-
ing chemotherapy and in patients with head-and-neck cancer under-
going radiotherapy indicated a shorter survival for patients receiving 
ESAs (10, 11). Thus concerns about the safety of ESAs were raised 
and were further substantiated by the demonstration of erythropoietin 
receptors on the surface of tumor cells. However, the recent meta-anal-
ysis did not prove a detrimental effect of ESAs on survival (HR 1,08, 
95% CI 0,99-1,18) (7). Two recent trials reported a neutral effect of 
ESAs on survival and conﬁrmed the safety of ESAs in anemic patients 
undergoing chemotherapy (12, 13). One of these trials (BRAVE trial) 
assessed epoetin beta in patients with metastatic breast cancer undergo-
ing chemotherapy (12) and the other trial studied the impact of darbe-
poetin alfa on survival of patients with extensive disease of small-cell 
lung cancer undergoing palliative platinum-based chemotherapy (13). 
Based on the currently available data, several pre-cautions with regard 
to the use of ESAs should be taken. Firstly, ESAs should be used 
according to published guidelines for patients with chemotherapy-in-
duced anemia. Secondly, treatment with ESAs should aim at a target 
Hb level of 12 g/dl. Thirdly, the use of ESAs in non-anemic cancer 
patients and in anemic patients not receiving chemotherapy is not rec-
ommended. Finally, the role of erythropoetin receptors has to be further 
studied. However, all these precautions should not result in withholding 
ESAs in patients with chemotherapy-induced anemia for whom both 
the clinical beneﬁt and safety of ESAs have been demonstrated. 
